Genomic scars in the somatic tumor genome report historic and persistently active DDR activities or deficiencies, and therefore, might be insensitive as predictors in the presence of reversion of DDR function such BRCA1 or BRCA2 “reversion mutations” or loss of methylation of BRCA1 (19) and may not be optimum for directing treatment options. The gene discussed is BRCA1; the disease is neoplasm.